Objectives: To evaluate maternal serum pregnancy-associated plasma
protein-A (PAPP-A) levels at 11–14 weeks of gestation in women with common
congenital anatomic uterine abnormalities (AUAs).
Methods: First trimester screening markers were compared between 12
AUA pregnancies and 60 age matched controls.
Results: PAPP-A level and birth weight were significantly lower in
AUA compared to control pregnancies (P
Pregnancy-compatible and incompatible congenital uterine abnormalities (AUAs) are present in 4–7% of women worldwide [1]. The role of pregnancy-compatible AUAs in placental development, pregnancy outcome and susceptibility to preeclampsia remains unclear and is poorly documented.
The advent of first trimester screening, including ultrasonography and
biochemical markers like pregnancy-associated plasma protein-A (PAPP-A) and free
Pregnancy-associated plasma protein-A (PAPP-A) is synthesized primarily by the syncytiotrophoblasts [4, 5] and increases in maternal serum throughout pregnancy [6]. Previous studies demonstrated positive association between low maternal serum PAPP-A concentration and elevated risk of intrauterine growth restriction, extreme preterm delivery, preeclampsia and stillbirth [7, 8, 9, 10, 11, 12, 13, 14].
To address the role of AUA’s in pregnancy disorders, we compared first trimester PAPP-A concentrations, among women with common congenital AUA’s and their age matched controls with normal uterus in the context of a retrospective study.
Two groups of study participants (N = 72) were recruited in the tertiary referral
center of Central Greece (Thessalia University Hospital), during a period of
three years. Cases (N = 12) with known AUA and age matched women controls (N = 60)
with normal uteri were included in each group. No apparent deviations among first
trimester nuchal transluscency of study participants were detected in study
groups. Measurements of nuchal transluscency above 95
Control (N = 60) | AUA (N = 12) | P | |
N (%) | N (%) | ||
Parity | |||
1 | 48 (80) | 12 (100) | 0.826 |
2 | 10 (16,66) | ||
3 | 2 (3,33) | ||
Age (years), mean (SD) | 31,8 (55,8) | 31,8 (6,3) | 0.941 |
Fetal sex | |||
Boys | 31 (51.6) | 7 (58,3) | 0.661* |
Girls | 29 (48,4) | 3 (42,7) | |
Week of gestation at delivery, | |||
median (IQR) | 39 (38–40) | 32 (31–34) | |
Preeclampsia development | |||
No | 60 (100) | 12 (100) | |
Yes | 0 (0) | 0 (0) | |
Preterm delivery | |||
No | 56 (93,3) | 2 (16,67) | |
Yes | 4 (6,7) | 10 (83,33) | |
Birth weight (gr), median | 3300 | 1930 | |
(IQR) | (2840–3900) | (1260–3030) | |
For the comparisons of proportions chi-square test, student’s t-test, Mann-Whitney test and Fisher’s exact tests were used. Statistical significance was set at 0.05 and analyses were conducted using SPSS statistical software (version 22.0).
Seventy two subjects were studied during a three year period. Cases (N = 12)
included the four of the most common types of congenital uterine malformations
indicated in the material and methods section. The clinical and demographic data
of known AUA carriers were compared with those of our age matched control group
of women with anatomically normal uterus (N = 60) in Table 1. When we compared
PAPP-A MoM values regarding preterm and term delivery in the two groups there was
no significance difference (Table 2). No differences were recorded in
ultrasonographic measurements and maternal demographics between the two groups.
Doppler measurements were performed in both study groups without revealing any
notable differences. The maternal serum PAPP-A MoM in the AUA group was lower
than in controls (0.412
PAPP-A (MoM). Box plots of maternal serum PAPP-A levels (MoM) in cases (N = 12) with
common pregnancy-compatible congenital uterine abnormalities (AUA) and controls
with normal uterus (N = 60); MoM of PAPP-A in AUA cases was significantly lower
than in controls (0.412
Control Term (N = 56) | Control Preterm (N = 4) | AUA Term (N = 2) | AUA Preterm (N = 10) | |
PAPP-A MoM values | 1,08 | 0,95 | 0,415 | 0,411 |
Birth weight (g), median | 3460 | 2880 | 3030 | 1260 |
We assessed the relative distribution of first trimester maternal serum PAPP-A in a Caucasian population of women with and without common pregnancy-compatible congenital anatomic uterine malformations from Central Greece. Our present study suggests that AUA is among the main influencers, like preeclampsia, chromosomal abnormalities, preterm labor that can influence PAPP-A concentration.
We observed that carriers of common congenital AUA’s present significantly lower PAPP-A concentrations (Fig. 1) and considerably lower birth weight compared to their age matched controls with normal uterus (Table 1). When we divided the two groups regarding term and preterm delivery, results revealed no change regarding our previous observation for PAPP-A concentration (Table 2). To understand the biological significance of our observations and assess the relatively lower concentration of PAPP-A in AUA’s, the central role of uterine anatomy in embryo development must be taken into account. If, according to popular acceptance, we view uterus as “home” of developing placenta implanted embryo-resident and PAPP-A concentration as an indicator of placental development, we can easily appreciate the critical role of uterine anatomy to support and maintain growing resident-embryo needs.
All anatomical uterine deviations presently studied, were associated with reduced uterus size and dimension, leading to smaller placental volume. In this context, our findings of reduced first trimester PAPP-A concentration (Fig. 1) and increase in preterm labor of AUA carriers leading to reduced birth weight are in direct line with our working hypothesis of an existing association between uterus size and dimension and PAPP-A concentration as pregnancy marker. In addition the common trend of an association between low PAPP-A and poor placentation leading to preeclampsia [17] was not observed in our AUA study group (Table 1). In line to our working hypothesis, we propose that the low PAPP-A concentration of AUA cases recorded in Fig. 1 resulted from the small size and volume of placenta rather than from poor placentation.
Our AUA MoM PAPP-A values (Fig. 1) fall within the range of 0,412 adjusted Mom PAPP-A level used as predictor for preeclampsia risk, by RCOG, FMF, ACOG guidelines.
The eventual association of women with anatomical uterine deviations leading to increased uterus size and dimension and bigger placenta carrying multiple pregnancies with elevated PAPP-A concentrations at 11 to 14 weeks of gestation further supports and expands our hypothesis [18].
While clear differentiation between AUA and embryonic development as the causative cause of our findings cannot be made, placental size differences due to reduced available endometrial surface in congenital AUA’s are likely to play a role. Finally at the clinical level, our findings suggest that a low first trimester PAPP-A concentration in AUA carriers is a valuable marker of pregnancy complications.
SS conceived of the study, SS, MS, AG and AD collected the data and analyzed the results. SS, DNV and NVC wrote the initial manuscript draft. All authors edited the draft and approved the final version. All authors made substantive intellectual contributions, read and approved the final version of the manuscript.
The study was performed with respect to the ethical standards of the Declaration of Helsinki, as revised in 2008. Also, a written informed consent was obtained from the study participants.
Thanks to all the peer reviewers for their opinions and suggestions.
This research received no external funding.
The authors declare no conflict of interest.